- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Al B. Benson Discusses Ongoing Work That Could Affect Future NCCN Guidelines
Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.
EP: 1.Pemigatinib: EMA Panel Offers Conditional Nod for Pemigatinib
EP: 2.Dr Al B. Benson on Neoadjuvant Treatment in Hepatobiliary Cancers
EP: 3.NCCN Updates in Bile Duct Cancer Put Focus on Precision Medicine
EP: 4.Dr Michael D’Angelica on the Importance of NCCN Guideline Updates and Progress in Hepatobiliary Cancer
EP: 5.Dr Al B. Benson Discusses Ongoing Work That Could Affect Future NCCN Guidelines
Al B. Benson, MD, FACP, FASCO, chair of the National Comprehensive Cancer Network (NCCN) hepatobiliary cancer guidelines panel, professor of medicine, and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.
Transcript
As you look ahead, what ongoing research do you anticipate will affect the next round of guideline updates?
I think in terms of the work that's ongoing, certainly there's more work looking at subtypes of patients. There are subgroups of patients, for example, with cholangiocarcinoma, including now, the BRAF population, patients with HER2-positive tumors and their ongoing trials. So, I think the identification further subsets, looking at combinations with immunotherapy—whether these are combinations with other immunotherapeutic drugs with, for example, TKIs, or chemotherapy combinations. These are all ideas that are under investigation currently.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma
November 26th 2024In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Read More
